PATENT CLAIM ANALYSIS

Application Number: 15731991
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-03
Patent Classification: ["424", "094200"]

Abstract:
The Cloning and Expression of Comosain's Minigene and the Methods and Compositions for treating and/or preventing various types of cancer which comprise administered an effective amount of Glyco-polypeptides and Bioflavonoids such as Comosain, Ananase, Bromelainases, Trypsin, Pepsin, Quercetin, Rutin, Naringenin, Genistein, Hesperetin, etc and/or a mixture thereof.

Claim (Index 11):
11 ). DNA sequencing.: Restriction fragments were cloned into M 13 phage vectors by using  Escherichia coli  strains JM 103 and/or JM 109 as host. (Messing, J. of methods enzymology 1983) and were sequenced by the dideoxy method of Sanger et al. some regions were sequenced by kinase labeling or end-fill labeling of restriction fragments followed by chemical cleavage as described by Maxam and Gilbert. (J. of methods of enzymology 1980).\n 985). The final Comosain Recombinants were collected, extracted, washed with ethyl alcohol, and purified by AKAT Prime (GE Co.) and/orFPLC-cation-exchange chromatography, to produce of F4, F5, (other bromelainases) and F-9a, F-9b (Ananase and Comosain) for future use.

Metadata:
- Claim Count in Document: 13.0
- Percentile: 95.0
- Lexical Diversity: 1.37209
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15272826', '14003629', '12861152', '11214831', '10617943']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7169029859432797
- 35 USC 102 Novelty (BERT): 0.4940255077461433
- Combined Prediction Score: 0.6946152381235661
- Mean Citation Score: 172.64342000000005
- Max Citation Score: 186.47795
- Similarity Product: 121.1461185279399

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 0

Dataset: test